interaction with proteins -mediators of apoptosis (Miyashita et al, 1994a (Miyashita et al, , 1994b Miyashita and Reed, 1995; Amundson et al, 1998) . Bcl-2 and bcl-x L proteins are inhibitors of programmed cell death, while bax belongs to promotors. It is suggested that both bcl-2 and bax proteins may participate in mitochondrial pore formation, and thus influence the execution step of apoptosis. Bcl-2 and bcl-x L anti-apoptotic proteins may be blocked by complex formation with bax (Reed, 1997) .
Little is known on apoptosis regulation in vivo. p53 gene alterations are very frequent in ovarian cancer -they have been found in 81% of serous type tumours in our own material, and are rather an early step in the development of ovarian cancer (Kupryjanczyk et al, 1993 (Kupryjanczyk et al, , 1995a reviewed in Kupryjanczyk, 1996) . One may expect that p53 gene mutations will negatively influence p53-dependent spontaneous and induced apoptosis. It is assumed that poor response to DNA-damage in tumours bearing a p53 gene mutation may cause genomic instability and tumour progression, as well as resistance to DNA damage-inducing therapy. However, studies on p53 status and response to cisplatin-based chemotherapy have not given so far equivocal results (Righetti et al, 1996; De Feudis et al, 1997) . To our knowledge, spontaneous apoptosis has not been evaluated in relation to p53 gene mutation neither in ovarian or other tumour samples. Also, nothing is known about possible prognostic value of spontaneous apoptosis in ovarian Spontaneous apoptosis in ovarian carcinomas: a positive association with p53 gene mutation is dependent on growth fraction cancer. The aim of this study was to evaluate associations between spontaneous apoptosis and p53 gene mutation, p53 protein accumulation, growth fraction, bcl-2 expression, clinico-pathological parameters and overall survival in ovarian carcinomas.
MATERIALS AND METHODS

Patients population
Patients ranged in age from 17 to 79 years (mean 56.9). The study was performed on 71 tumours prior to chemotherapy: 64 ovarian, four tubal and three disseminated peritoneal carcinomas of mullerian type (i.e. serous). Tumours were staged according to the criteria of the International Federation of Gynaecologists and Obstetricians (Peterson et al, 1988; Creasman, 1989; Hirai et al, 1989) . Ten tumours were in stage I, six were in stage IIC and 55 were in stage III or IV. Follow-up was available for 61 ovarian cancer patients and ranged from 3 to 96 months (mean 25); 24 patients died of the disease.
Histopathological data
Tumours were classified according to the criteria of the World Health Organization (Russell, 1994) . Fifty-one tumours were of the serous type and 20 of other types (seven endometrioid, four mucinous, four clear cell, one transitional cell, one carcinosarcoma, three undifferentiated). Tumour sections used for the apoptosis and immunohistochemical evaluations were re-examined as to the histological and nuclear grades according to the criteria given by Russell (1994) and Barber et al (1975) respectively (Table 1) .
Molecular genetic analysis
Thirty-one tumours were previously characterized as to the p53 gene mutation (Kupryjanczyk et al, 1993 (Kupryjanczyk et al, , 1995 . The other 40 tumours were analysed by single strand conformational polymorphism (SSCP) method and direct sequencing. Briefly, exons 4-11 of the p53 were amplified by polymerase chain reaction (PCR; with application of Perkin-Elmer PCR kit) on a programmable thermal cycler (Biometra) with denaturation at 94°C, annealing at 52-65°C (depending on the exon) and extension at 72°C, each for 30 s (primer sequences and other details available from the author). PCR products, denatured with 0.1 M sodium hydroxide, were loaded to polyacrylamide gels (1:39 N,N′-methylenebisacrylamide to acrylamide) (12% without glycerol and 10% with 10% glycerol). Electrophoresis was performed at 100 V for 16-24 h at room temperature (RT). Normal DNA, amplified in the same PCR reaction, denatured and non-denatured was run on each gel as a control. The bands were visualized by silver-staining method compilated from several procedures. Sequencing of the SSCP variants was performed with the use of dideoxy chain termination method according to the procedure described in the Sequencing kit with sequenase version 2.0 (UBS, Amersham) (sequences of primers used available from the author). Radioactive labelling reaction was performed at 0°C for 5 min using α-32 P-dATP. The reaction products were electrophoresed on 8% polyacrylamide gels (N,N′-methylenebisacrylamide and acrylamide ratio 1:19, 1 × TTE, 7M urea) at 80 W for 80-110 min. The gels were exposed to X-ray films for 1-7 days.
Apoptosis analysis
Apoptotic cells were identified in paraffin-embedded material with the use of the TUNEL method with application of a commercially available kit (ApopTag Plus, Oncor, cat no. S7101). Apoptotic cells were counted at a 400ϫ magnification with the use of a 0.49 cm 2 graticule containing 36 grid points. Only cells with a defined apoptotic morphology and of the total size corresponding to the size of tumour cell nuclei were taken into account. The counting was performed in four different areas most rich in apoptotic cells, at least to 200 counts per area (may correspond to 6400-8000 of tumour cells evaluated in each case). Areas adjacent to necrosis were avoided. Apoptotic index (AI) was defined as a proportion of the apoptotic cells to the number of tumour cell nuclei intersecting grid points.
Immunohistochemical analysis
P53 protein accumulation, bcl-2 and Ki-67 expressions were detected immunohistochemically on paraffin-embedded material after heat-mediated antigen retrieval. We used PAb1801 monoclonal antibody (1:500, Genosys) for the p53 protein, anti-bcl-2 monoclonal antibody (1:80, Dako, Glostrup, Denmark) for bcl-2 protein, and MIB-1 antibody (1:50, Immunotech, Marseille, France) for Ki-67 antigen. Deparaffinized sections were boiled 2 × 5 min (for p53 and bcl-2) or 3 × 5 min (for Ki-67) in a citrate buffer (pH 6.0) at 700 W. Biotinylated goat anti-mouse IgG (1:1500, cat. no. 816), peroxidase conjugated streptavidin (1:500, cat. no. 309) (both from Immunotech, Marseille, France), and DAB were used as a detection system. Normal mouse IgG (1:25, Dako, Glostrup, Denmark) was used as a negative control. P53 protein accumulation was described as present or absent; percentage of p53-positive cells was estimated semiquantitatively. Bcl-2 expression was evaluated semiquantitatively and the following staining categories were created: (1) negative, trace, or focal positive; diffusely positive, either (2) weak, (3) moderate or (4) strong. MIB-1-positive cells were counted in three different foci most rich in proliferating cells to 500 counts per focus. A mean proliferation index (PI) was defined for each case.
Statistical analysis
Number of apoptotic cells to the number of tumour cell nuclei was evaluated as a dependent variable in a weighed multiple logistic regression model (Williams, 1982) . Independent variables included: histological tumour type (serous vs others), two binary variables indicating histological tumour grade (1 vs other, 2 vs other) and nuclear grade (2 vs other, 3 vs other), p53 protein accumulation (absent vs present), two binary variables indicating p53 gene status (no mutation vs mutation, a mutation in exons 7-8 vs another status) and bcl-2 expression (negative, trace or focal vs diffuse of any intensity). This analysis has been performed twice, without and with inclusion of the proliferation index as an independent variable.
Bcl-2 expression was studied as a dependent variable with the use of the Kruskal-Wallis test (Siegel and Castellan, 1988) . This analysis included histological tumour type and p53 gene mutation as independent variables. Associations of bcl-2 expression with histological or nuclear grades and with a histological type were studied by a correlation coefficient gamma and Fisher's test respectively (Goodman and Kruskal, 1979; Mehta and Patel, 1983) . For overall survival analysis we used Cox's model and logrank test stratified according to FIGO stage. The level of significance was set at 5%.
RESULTS
p53 status
p53 gene alterations have been found in 28 of the 40 new tumours (70%); the mutational spectrum was similar to that already published for ovarian cancer, except that exon 5 mutations accounted for about 50% of the alterations detected. Table 2 shows a novel complex mutation of the p53 gene and four rare alterations that have not been reported for ovarian cancer (other mutations will be published elsewhere).
Altogether, among 71 tumours p53 gene mutations were present in 51 (72%); 31 had mutations in exons 4-6 (44%) and 20 in exons 7-8 (28%). Forty-two mutations were missense and nine were nonsense; 33 tumours showed loss of heterozygosity at p53. In 20 tumours (28%) no mutation has been detected in the sequences studied, i.e. exons 4-11. P53 protein accumulation was observed in 46 tumours (64%), and the percentage of positive cells ranged from 30-100% (mean 81%).
Bcl-2 expression
Twenty tumours did not express bcl-2 protein, 11 showed only trace reactivity, and the staining was focal in another 11 tumours. Apparent diffuse bcl-2 expression of any intensity was observed in 29 tumours (41%); it was weak in 17, moderate in eight and very strong in four tumours. The latter group included a poorly differentiated serous carcinoma, and three cases of poorly differentiated endometrioid carcinoma. The association of strong bcl-2 expression with endometrioid tumour type was statistically significant (P = 0.002). Bcl-2 expression was not associated with other parameters studied, in particular with p53 gene mutation or p53 protein accumulation.
Apoptotic index
The AI ranged 0.024-0.182 (mean 0.112). In univariate evaluation mean values of the AI for good, moderate and poor histological differentiation were 0.06, 0.12 and 0.11 respectively; mean AI value for tumours without p53 gene mutation was 0.10, while for tumours with p53 gene mutation it was 0.11 (without differences in respect to missense or nonsense mutation, or heterozygosity status); mean AI value for tumours without, and with diffuse bcl-2 expression was 0.11 and 0.10 respectively. The multivariate logistic regression model for proportion of apoptotic cells retained the following variables at a 5% level of significance: good histological differentiation (P = 0.0006), the serous tumour type (P = 0.002), the proliferation index (P = 0.023) and diffuse bcl-2 expression (P = 0.025) (parameters estimates are shown in Table  3 ). In the group of tumours other than serous, clear cell and endometrioid carcinomas had the highest mean AI (0.16 and 0.12 respectively). In mucinous carcinomas the AI was lower (0.09) than in the serous type (0.10). In contrast to low histological grade, low nuclear grade was positively associated with the AI, but it was of borderline significance (P = 0.071). The presence of the p53 gene mutation did positively influence the AI, but it was at the border of significance (P = 0.082). This association was much stronger (P = 0.011) in the initial analysis, without inclusion of the proliferation index into the model. P53 protein accumulation did not influence the AI.
Survival analysis
Overall survival analysis was performed on the group of 61 ovarian cancer patients. It included the AI (≤ 0.10 vs > 0.10), clinical stage (FIGO I, II vs III, IV), histological grade (1, 2 vs 3), p53 protein accumulation (absent vs present), p53 gene mutation (absent vs present) and the proliferation index (≤ 46.46 vs > 46.46). The AI and PI were cut off arbitrarily at the 33rd percentile. The only factor that influenced overall survival was FIGO stage (RR = 5.7; 95% confidence interval (CI) 1.27-25.59; P = 0.023) and p53 protein accumulation, when the group was stratified for FIGO (log-rank = 4.34, P = 0.037).
DISCUSSION
Wild-type p53 may simultaneously induce growth arrest and apoptosis within the same cell (Liebermann et al, 1995) . Biochemical pathways for these two processes are different: the first one involves transcriptional activation of waf1, the other -interactions with bcl-2 family genes. These pathways are independent, but may communicate, and a switch of one signal to the other may occur (Bellamy, 1996; Amundson et al, 1998) . P53-mediated control of cell proliferation and death involves other proteins also -to date at least 20 p53 effector genes have been recognized, which participate in regulation of growth arrest, apoptosis or both (Amundson et al, 1998 ). The present and other studies on human tumours show a spectacular (opposite to the physiological one) effect of impaired p53 function on tumour proliferation (Henriksen et al, 1994; Kupryjanczyk et al, 1995b; Rohlke et al, 1997) . The same cannot be observed in relation to apoptosis. We and others have not found an association between apoptosis and p53 protein accumulation (Diebold et al, 1996; McMenamin et al, 1997; Yamasaki et al, 1997) . Our study has shown that p53 gene mutation does not contribute to attenuation of spontaneous apoptosis in ovarian carcinomas. On the contrary, it has a positive influence on this process mainly by increasing growth fraction. Thus, our results suggest that spontaneous apoptosis in ovarian carcinomas does not depend on wild-type p53 protein. This is intriguing, because spontaneous apoptosis in the tumours studied might have also been a response to DNA damage, inappropriate oncogene activation and different environmental changes, such as hypoxia, that specifically induce p53.
Evidence is accumulating that cell proliferation and apoptosis are linked. Examples of proteins with both growth-promoting and pro-apoptotic function are c-myc, adenovirus E1A, and E2F-1 transcription factor (Evan and Littlewood, 1998) . Other authors did report a positive association between apoptosis and growth fraction or mitotic index in ovarian carcinomas (McMenamin et al, 1997; Yamasaki et al, 1997) .
Our study has shown that degree of histological differentiation and histological tumour type are among major determinants of spontaneous apoptosis in ovarian carcinomas. The apoptotic index was negatively associated with good histological differentiation, which was also observed by other authors (Diebold et al, 1996; Yamasaki et al, 1997) . We have shown that this association is not dependent on low growth fraction in well differentiated tumours. In contrast to good histological differentiation, good nuclear differentiation showed a positive influence on spontaneous apoptosis, although it was at the border of significance. The AI may depend on histological tumour type, too. It was higher in carcinomas other than serous. In fact, among that group of tumours the clear cell and endometrioid carcinomas had the highest AI, while mucinous carcinomas had the lowest, even lower than the serous type. High AI in clear cell and endometrioid carcinomas may be dependent on strong bax expression in most cases of these histological types, as shown by Tai et al (1998) .
It has been shown for some cell lines that p53 may repress transcription of bcl-2, and activate that of bax (Miyashita et al, 1994a (Miyashita et al, , 1994b Miyashita and Reed, 1995) . We have not found an association between p53 gene mutation or protein accumulation and bcl-2 expression. Bcl-2 expression was dependent on histological tumour type: the strongest expression was seen in endometrioid carcinomas (described also by Diebold et al, 1996) , despite poor tumour differentiation and the relatively high AI. Generally tumours with diffuse bcl-2 expression had significantly lower AI, which is in accord with its anti-apoptotic function. Thus, evidence is accumulating that there are major differences among histological tumour types not only in respect to p53 function, but also apoptosis and expression of apoptosis-related genes.
Apoptosis and growth fraction did not gain a prognostic significance in our analysis. We have hypothesized that p53 protein accumulation may not have a prognostic value because of different biological significance of p53 gene mutations. In our analysis, the presence of p53 gene mutation did not influence overall survival time. The only parameters prognostically significant were clinical stage and p53 protein accumulation. Prognostic value of p53 protein accumulation has been a matter of controversy. In this aspect, our result supports studies by Klemi et al (1995) , Herod et al (1996) and Rohlke et al (1997) . Therefore, it seems that p53 protein accumulation (with or without underlying gene alterations) is a more adequate manifestation of impaired p53 protein function than gene alterations that include also nonsense errors without protein accumulation. 
